Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-12-17 4:22 pm Purchase | 13G | Pieris Pharmaceuticals, Inc. PIRS | Dellora Investments Master Fund LP | 141,079 1.300% | 141,079 (New Position) | View |
| 2024-12-06 2:21 pm Purchase | 13G | Pieris Pharmaceuticals, Inc. PIRS | Dellora Investments Master Fund LP | 141,079 10.700% | 32,105 (+29.46%) | View |
| 2024-12-05 1:47 pm Purchase | 13G | Tenax Therapeutics, Inc. TENX | Dellora Investments Master Fund LP | 234,793 6.900% | 234,793 (New Position) | View |
| 2024-08-07 2:16 pm Purchase | 13G | Pieris Pharmaceuticals, Inc. PIRS | Dellora Investments Master Fund LP | 108,974 8.300% | 108,974 (New Position) | View |
| 2024-02-14 10:09 am Sale | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 0 0.000% | -43,250 (Position Closed) | View |
| 2023-02-13 4:16 pm Unchanged | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 43,250 5.200% | 0 (Unchanged) | View |
| 2022-08-22 1:17 pm Purchase | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Dellora Investments Master Fund LP | 43,250 5.200% | 43,250 (New Position) | View |